Compare IQV & RKLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | RKLB |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 37.3B |
| IPO Year | 2013 | 2020 |
| Metric | IQV | RKLB |
|---|---|---|
| Price | $264.36 | $46.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 22 |
| Target Price | ★ $311.89 | $102.15 |
| AVG Volume (30 Days) | 1.2M | ★ 15.1M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.67 | 2.63 |
| EPS | ★ 5.24 | N/A |
| Revenue | ★ $9,739,000,000.00 | $601,799,000.00 |
| Revenue This Year | $7.18 | $59.39 |
| Revenue Next Year | $6.34 | $38.72 |
| P/E Ratio | $50.37 | ★ N/A |
| Revenue Growth | ★ 41.60 | 37.96 |
| 52 Week Low | $154.50 | $37.57 |
| 52 Week High | $284.50 | $150.85 |
| Indicator | IQV | RKLB |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 38.89 |
| Support Level | $252.55 | $49.25 |
| Resistance Level | $276.99 | $77.02 |
| Average True Range (ATR) | 10.38 | 3.40 |
| MACD | -1.50 | 0.07 |
| Stochastic Oscillator | 35.53 | 25.84 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.